Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer

SRC tyrosine kinase is frequently overexpressed and activated in late-stage, poor prognosis ovarian tumours, and preclinical studies have supported the use of targeted SRC inhibitors in the treatment of this disease. The SAPPROC trial investigated the addition of the SRC inhibitor saracatinib (AZD05...

Descripción completa

Detalles Bibliográficos
Autores principales: McGivern, Niamh, El-Helali, Aya, Mullan, Paul, McNeish, Iain A., Paul Harkin, D., Kennedy, Richard D., McCabe, Nuala
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797008/
https://www.ncbi.nlm.nih.gov/pubmed/29435137
http://dx.doi.org/10.18632/oncotarget.23524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797008/
https://www.ncbi.nlm.nih.gov/pubmed/29435137
http://dx.doi.org/10.18632/oncotarget.23524

Ejemplares similares